Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy.
about
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphomaFlavonol and imidazole derivatives block HPV16 E6 activities and reactivate apoptotic pathways in HPV⁺ cellsCD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathwaysDifferential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin BPromising novel therapies for the treatment of endometrial cancerPredominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.TRAIL in cancer therapy: present and future challenges.Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenograftsCombination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma.Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation.Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle.Novel treatment strategies for aggressive non-Hodgkin's lymphoma.Deciphering CD30 ligand biology and its role in humoral immunity.TRAIL receptor-targeted therapy.Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival.The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cellsTNF-alpha downregulates E-cadherin and sensitizes response to γ-irradiation in Caco-2 cells.New targets of therapy in T-cell lymphomas.Beyond chemotherapy: new agents for targeted treatment of lymphomaRole of CD30 targeting in malignant lymphoma.Brentuximab vedotin for the treatment of Hodgkin's lymphoma.Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.Effect of TRAIL in combination with DDP on the expression of MDR1 gene in gastric cancer cells.The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.TNF-α expression in the UCB-MSCs as stable source inhibits gastric cancers growth in nude mice.Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24.Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma.Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cellsTweak induces mammary epithelial branching morphogenesis.TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-beta in cervical carcinoma cells.Unraveling the binding mechanism of trivalent tumor necrosis factor ligands and their receptors.Utilizing CD30 expression as a rational target for therapy of lymphoma.Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour
P2860
Q24633761-86EFF70D-96EA-48B2-881F-B31F8E7EF24EQ28817517-DE5499C9-42B4-44AB-A8A0-417B0CCF0BC1Q33236909-A3BA5E83-7E1A-4F9B-9B59-BD90E53CF885Q33722067-486664E5-F5EA-4437-AFBF-F807EDF3C041Q33920661-E5E6958D-42D4-4183-B8DD-8DB8755180F9Q34132999-4697B8FB-59D1-48F2-B4E7-3B200BF4184AQ34291312-3AD6D66D-4AEA-4434-9D56-316EBEF328FFQ34465302-09020BA8-9B67-4C02-B413-1E091ABEBEBBQ34778364-4167063D-8E1B-40A5-B646-D1E1C583D829Q35865599-89A6C6BE-1E67-47AD-803B-1761A2AF1E54Q36118431-E4F3A660-3B91-43B3-BC0B-41A4EAB8BF5FQ36429727-A8997CA5-01EA-4A81-86BA-A5398B0CFF59Q36505738-5A94219D-5ED5-4B8E-9893-AF285E945278Q36572530-75EB28A9-80D3-4765-9454-D2997A82F10CQ36731304-1DEF467D-7F87-425D-B307-9C156457DFDEQ36787532-46765001-A2BB-4176-AA3D-5BFAD01DB67FQ37376902-17A358DD-6F33-4F5C-93BB-AEFBA3DBE4DDQ37701472-5831E050-D2B8-4AA1-AA6C-F5D4EB037AF7Q37820097-D3E3CE07-E48A-4A47-9167-A6797883B8EDQ38191191-C94ABB6C-DCDD-479A-9868-2E728CFFD62CQ38476250-AE483A4D-D1FE-4DF6-877D-3F021AB89CAAQ38795442-D83152E2-0164-47E0-8532-08E7EE66AF1FQ38951203-ED21AE22-0ABC-4378-BF5C-24DD2BFCAF7AQ39336527-B13E3CC9-267C-4663-AF1D-DB40CE94E290Q39358246-979EB563-82F7-4AC0-830D-CD1706856A22Q39977288-47CA09C8-EDBC-46C9-9B12-149B4C2319FCQ40330082-4732C8EF-923D-4F72-9B6F-72C1EBAF1FAAQ40438367-7AE1CAF9-0791-45A9-BD54-D7DA62E9F519Q40453290-8A2BF007-A4B4-48E6-A97F-186F896637F2Q40453338-55D28C96-AB72-49C9-A26C-C2B851D052EEQ41573234-AA38854B-16A1-4FC2-89EE-B9033055087EQ45764153-BB3CC4EA-9683-4BF9-BFF7-C8A601A405B4Q48157671-4328C16D-1FCC-455C-81A6-487F10819911Q57174410-97AF90D7-008D-4213-A347-15F9B3065B60
P2860
Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Emerging applications of the t ...... d receptors in cancer therapy.
@ast
Emerging applications of the t ...... d receptors in cancer therapy.
@en
type
label
Emerging applications of the t ...... d receptors in cancer therapy.
@ast
Emerging applications of the t ...... d receptors in cancer therapy.
@en
prefLabel
Emerging applications of the t ...... d receptors in cancer therapy.
@ast
Emerging applications of the t ...... d receptors in cancer therapy.
@en
P356
P1476
Emerging applications of the t ...... d receptors in cancer therapy.
@en
P2093
Anas Younes
Marshall E Kadin
P304
P356
10.1200/JCO.2003.09.037
P407
P577
2003-09-01T00:00:00Z